TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02213289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806
Description: ABT-806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806
Description: ABT-806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Bemarituzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Intervention type: DRUG
Group type: OTHER
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
Study: NCT02106897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Descriptions
Study: NCT02013791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle of cyclosporine administered as per protocol

Intervention type: OTHER
Group type: OTHER
Intervention: Sham
Description: Sham administered to non-study eye as per protocol on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol
Study: NCT04601480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture Nudge
Description: During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture Nudge
Description: During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMP Integration & Nudge
Description: During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMP Integration & Nudge
Description: During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
Study: NCT00828737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Gadovist in approved indications at approved dosages
Study: NCT00945100

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: 42 hours patching per week (averaging 6 hours patching daily)
Study: NCT03833479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Further Treatment
Description: No further treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
Study: NCT00118846

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25 gm soy protein supplement
Description: 25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Milk protein administered twice daily
Study: NCT00945100

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: 2 hours patching daily
Study: NCT03013855

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FIT-SOC
Description: Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
Study: NCT01931488

Intervention type: OTHER
Group type: OTHER
Intervention: MIBG label with I123 or I124
Description: PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.

Intervention type: DEVICE
Group type: OTHER
Intervention: SPECT imaging
Study: NCT03013855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIT-DRE
Description: Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
Study: NCT00802932

Intervention type: DEVICE
Intervention: Non-contrast Computed Tomography (CT) Scans (Metallic Markers)
Description: Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.

Intervention type: DEVICE
Intervention: Non-contrast CT Scans (Metallic Markers)
Description: Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
Study: NCT04338139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone regeneration
Description: bone regeneration using bio-oss collagen
Study: NCT02241213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS-r)
Description: 10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcranial Magnetic Stimulation
Description: 10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
Study: NCT02274831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Email Reminder of need to follow up with primary physician
Study: NCT02600689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive exercise training
Study: NCT02013791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol
Study: NCT01092559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide generated by the GeNO nitrosyl delivery system
Description: single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
Study: NCT02630498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial plexus block
Description: Patients receiving brachial plexus block for hand/arm surgery
Study: NCT02643082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003) 14.4/9.6μg
Description: Glycopyrronium and Formoterol Fumarate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Comparator: Placebo MDI which contains no active ingredients
Study: NCT02239757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left radial approach
Description: Primary PCI performed through left radial approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right radial approach
Description: Primary PCI performed through right radial approach.
Study: NCT01324999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 20mg/day for one month then 40mg/day for additional 4 months
Study: NCT00632242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment.
Study: NCT01830790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Single dose of 100mg Sildenafil citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: Single dose of 100mg Sildenafil citrate
Study: NCT03551288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-911
Description: Tablet
Study: NCT01244594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling with functional electrical stimulation
Description: Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling with functional electrical stimulation
Description: Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
Study: NCT00957944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rotigotine transdermal patch (Neupro®)
Description: Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rotigotine transdermal patch (Neupro®)
Description: Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
Study: NCT03628482

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRF
Description: For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
Study: NCT03581695

Intervention type: OTHER
Intervention: Blood test
Description: Blood test

Intervention type: OTHER
Intervention: Blood test
Description: Blood test

Intervention type: OTHER
Intervention: Blood test
Description: Blood test
Study: NCT03759886

Intervention type: DRUG
Intervention: Paromomycin Sulfate Powder
Description: The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
Study: NCT01034566

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Study: NCT02867813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
Study: NCT06658379

Intervention type: DIAGNOSTIC_TEST
Intervention: CD8+TEMRA
Study: NCT00223405

Intervention type: DEVICE
Intervention: crown placement

Intervention type: DEVICE
Intervention: crown placement
Study: NCT00632242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
Study: NCT04304807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg
Description: Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Traditional antibiotic treatment
Description: Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
Study: NCT04541862

Intervention type: OTHER
Intervention: Intensive care
Description: intensive care for critically ill patients in the intensive care units
Study: NCT04357678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qi Gong Programme
Description: Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Form Sun Style Tai Chi
Description: Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session.
Study: NCT00634530

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Advice
Description: The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
Study: NCT03714867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: 150 mg concealed pregabalin capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Concealed placebo capsule
Study: NCT03973385

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy
Description: patients recieving cryotherapy for skin anesthesia for artérial blood gas

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: patients recieving cryotherapy for skin anesthesia for artérial blood gas
Study: NCT04355845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: 25 milligrams (mg) single dose tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 400 mg single dose